92,770 results match your criteria Lung Cancer Oat Cell Small Cell


SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.

Lung Cancer 2022 May 5;169:13-21. Epub 2022 May 5.

Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université Paris Cité, Team Inflammation, Complement and Cancer, F-75006 Paris, France; Department of Pathology, Hôpitaux Universitaire Paris Centre, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.

Introduction: SMARCA4/BRG1 loss of expression occurs in 5-10% of non-small cell lung carcinomas (NSCLC). We investigated the pathological, molecular and immune environment characteristics of this deficiency among NSCLC, its impact on overall survival (OS) of resected patients and the sensitivity to anti-PD1 inhibitors in metastatic patients.

Materials And Methods: BRG1 expression was assessed by immunohistochemistry to identify SMARCA4-deficient NSCLC (SD-NSCLC) from the cancer tissue collection of Cochin Hospital (Paris, France). Read More

View Article and Full-Text PDF

Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.

BMC Cancer 2022 May 20;22(1):564. Epub 2022 May 20.

Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

Background: Ribosomal protein S6 (S6), a downstream effect media of the AKT/mTOR pathway, not only is a part of 40S small subunit of eukaryotic ribosome, but also involves in protein synthesis and cell proliferation during cancer development.

Methods: In present study, we explore the association between phosphorylated S6 (p-S6) protein expression and clinicopathological features as well as prognostic implications in NSCLC. P-S6 was detected in tissue microarrays (TMAs) containing 350 NSCLC, 53 non-cancerous lung tissues (Non-CLT), and 88 cases of matched metastatic lymph node lesions via immunohistochemistry (IHC). Read More

View Article and Full-Text PDF

Iris Metastases from Small Cell Lung Carcinoma.

Am J Med Sci 2022 May 17. Epub 2022 May 17.

Department of Ophthalmology, Centro Hospitalar e Universitário de São João; Anatomy Unit, Biomedicine Department, Faculty of Medicine of University of Porto.

View Article and Full-Text PDF

MiR-26b-5p in small extracellular vesicles derived from dying tumor cells after irradiation enhances the metastasis promoting microenvironment in esophageal squamous cell carcinoma.

Cancer Lett 2022 May 17:215746. Epub 2022 May 17.

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. Electronic address:

Radiation therapy is effective in achieving local control in esophageal squamous cell carcinoma; however, changes in the tumor microenvironment induced by radiation can also promote metastasis. Dying tumor cells play vital roles in promoting the survival of living tumor cells; however, few studies have investigated the effects of dying tumor cells on the tumor microenvironment. Since myeloid-derived suppressor cells (MDSCs) and macrophages constitute the pre-metastatic niche (PMN), we used a 4-nitroquinoline-1-oxide induced in situ tumor model to investigate the effects of irradiation on MDSCs and macrophages in esophageal squamous cell carcinoma (ESCC). Read More

View Article and Full-Text PDF

Molecular mechanism of Pulmonary diseases caused by exposure to urban PM in Chengdu-Chongqing Economic Circle, China.

Environ Int 2022 May 11;165:107292. Epub 2022 May 11.

Research Center for Atmospheric Environment, Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing 400714, China. Electronic address:

Chengdu-Chongqing Economic Circle (CD-CQ Economic Circle) is one of China's four major economic circles and five major urban agglomerations located in Southwest China's Sichuan Basin. The CD-CQ Economic Circle, with its strong economic development and dense population, suffers from severe PM pollution, which is known to cause chronic and acute respiratory ailments. This study examined the lung disease-related hub genes, functions, and pathways that are affected by PM in summer and winter in the two central megacities of Chengdu and Chongqing. Read More

View Article and Full-Text PDF

A graph-transformer for whole slide image classification.

IEEE Trans Med Imaging 2022 May 20;PP. Epub 2022 May 20.

Deep learning is a powerful tool for whole slide image (WSI) analysis. Typically, when performing supervised deep learning, a WSI is divided into small patches, trained and the outcomes are aggregated to estimate disease grade. However, patch-based methods introduce label noise during training by assuming that each patch is independent with the same label as the WSI and neglect overall WSI-level information that is significant in disease grading. Read More

View Article and Full-Text PDF

[Clinical efficacy of ct-guided transthoracic needle biopsy of peripheral lung lesions].

Khirurgiia (Mosk) 2022 (5):34-42

Moscow City Oncology Hospital No. 1, Moscow, Russia.

Objective: To evaluate the effectiveness of a step-by-step protocol for GT-guided transthoracic biopsy in verification of peripheral lung tumors.

Material And Methods: A retrospective analysis of the results of GT-guided transthoracic biopsies of focal lung neoplasms was performed between October 2019 and December 2020. The analysis included the results of 176 biopsies in 158 patients. Read More

View Article and Full-Text PDF
January 2022

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma.

Front Oncol 2022 3;12:833486. Epub 2022 May 3.

Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.

Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small-cell lung cancer (NSCLC). Here, we present information on the clinicopathologic characteristics and clinical outcomes of this type of cancer. Clinicopathologic data from 55 patients treated at a single cancer center from January 2011 to December 2018 were retrospectively analyzed. Read More

View Article and Full-Text PDF

Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.

Mod Pathol 2022 May 19. Epub 2022 May 19.

Department of Pathology, University of California San Francisco, San Francisco, CA, USA.

Neuroendocrine carcinomas (NEC) of the breast are exceedingly rare tumors, which are classified in the WHO system as small cell (SCNEC) and large cell (LCNEC) carcinoma based on indistinguishable features from their lung counterparts. In contrast to lung and enteropancreatic NEC, the genomics of breast NEC have not been well-characterized. In this study, we examined the clinicopathologic, immunohistochemical, and genetic features of 13 breast NEC (7 SCNEC, 4 LCNEC, 2 NEC with ambiguous small versus large cell morphology [ANEC]). Read More

View Article and Full-Text PDF

MiR-572 promotes the development of non-small cell lung cancer by targeting KLF2.

Authors:
B Sun J Zhao Z-Y Shao

Eur Rev Med Pharmacol Sci 2022 May;26(9):3083-3090

Department of Thoracic Surgery, Jining No. 1 People's Hospital, Jining, China.

Objective: The aim of this study was to uncover the role of miR-572 in regulating proliferative and migratory abilities in non-small cell lung cancer (NSCLC) and the possible mechanism.

Patients And Methods: Expression levels of miR-572 in 46 matched NSCLC and paracancerous samples were detected. The relationship between miR-572 level and clinical features of NSCLC was analyzed. Read More

View Article and Full-Text PDF

BAP18 induces growth of non-small-cell lung carcinoma through upregulating transcriptional level of CCND1/2.

Eur Rev Med Pharmacol Sci 2022 May;26(9):3074-3082

Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Objective: To elucidate the biological function of BAP18 (BPTF-associated protein of 18 kDa) in non-small-cell lung carcinoma (NSCLC) and the molecular mechanism.

Patients And Methods: Relative levels of BAP18 in NSCLC tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR), and its influence on pathological characteristics of NSCLC patients was analyzed. Correlation between BAP18 and Ki67 levels in NSCLC was assessed by Pearson correlation test. Read More

View Article and Full-Text PDF

The incidences of adverse events in small-cell lung cancer patients after radiotherapy and immunotherapy treatment: a systematic review and meta-analysis.

Eur Rev Med Pharmacol Sci 2022 May;26(9):3062-3073

Department of Respiratory and Critical Care Medicine, Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, Hubei, China.

Immunotherapy is important in treating small-cell lung cancer (SCLC), and its anti-tumor effects are better when combined with radiotherapy. However, the toxicity of this combination is little known. This study assessed the incidences of adverse events when adding radiotherapy to ICIs in patients with SCLC. Read More

View Article and Full-Text PDF

Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.

Comput Math Methods Med 2022 9;2022:2848220. Epub 2022 May 9.

Department of Infectious Disease, Wuhan Asia General Hospital, China.

Background: Relapsed and refractory small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. The prognosis of patients is poor. The 5-year survival rate is almost 0. Read More

View Article and Full-Text PDF

Entanglement of methylation changes and cGAS-STING signaling in non-small-cell Lung Cancer.

Authors:
Fang Hao

Comb Chem High Throughput Screen 2022 May 17. Epub 2022 May 17.

Department of Oncology, Tianjin Medical University General Hospital, Tianjin, China.

Background: cGAS-STING signaling has been primarily discovered as an important DNA sensing machinery bridging between innate and adaptive immunity. Beyond its antiviral response, recent evidence expanded its complicated role to cancer therapy.

Methods: UALCAN, The TCGA Wander, GEPIA, SMART, TIMER, Kaplan-Meier plotter, TCGA Data and cBioPortal were utilized in the investigation. Read More

View Article and Full-Text PDF

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.

J Hematol Oncol 2022 May 18;15(1):62. Epub 2022 May 18.

The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Background: Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic changes between non-small cell lung cancer (NSCLC) patients with varied response to neoadjuvant immunotherapy and discovered highly potential biomarkers with indicative capability in predicting outcomes.

Methods: In this study, 3 adenocarcinoma and 11 squamous cell carcinoma NSCLC patients were treated by neoadjuvant immunotherapy with variated regimens followed by surgical resection. Read More

View Article and Full-Text PDF

Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea.

BMC Pulm Med 2022 May 18;22(1):200. Epub 2022 May 18.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.

Background: The aim of this study was to investigate the characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer (SCLC) using a nationwide registry in Korea.

Methods: The Korean Association for Lung Cancer developed a registry in cooperation with the Korean Central Cancer Registry (KCCR) and surveyed approximately 10% of recorded lung cancer cases.

Results: From 2014 to 2016, the KCCR registered 1,043 patients newly diagnosed with SCLC among a total of 8,110 lung cancer patients. Read More

View Article and Full-Text PDF

Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients.

J Immunother Cancer 2022 May;10(5)

Department of Clinical and Molecular Medicine, Sant' Andrea Hospital-Sapienza University of Rome, Rome, Italy.

Background: Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the mechanisms of cancer immune evasion and resistance to immunotherapy. Here, we exploited malignant pleural effusions (MPEs) from lung adenocarcinoma (LUAD) patients as a model system to decipher TIME in metastatic NSCLC. Read More

View Article and Full-Text PDF

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.

Cell Rep 2022 May;39(7):110814

Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address:

Small cell lung cancers (SCLCs) have high mutational burden but are relatively unresponsive to immune checkpoint blockade (ICB). Using SCLC models, we demonstrate that inhibition of WEE1, a G2/M checkpoint regulator induced by DNA damage, activates the STING-TBK1-IRF3 pathway, which increases type I interferons (IFN-α and IFN-β) and pro-inflammatory chemokines (CXCL10 and CCL5), facilitating an immune response via CD8 cytotoxic T cell infiltration. We further show that WEE1 inhibition concomitantly activates the STAT1 pathway, increasing IFN-γ and PD-L1 expression. Read More

View Article and Full-Text PDF

Too much water drowned the miller: Akkermansia determines immunotherapy responses.

Cell Rep Med 2022 May;3(5):100642

Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, TX 77030, USA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, TX 77030, USA; Department of Immunology. The University of Texas MD Anderson Cancer Center, TX 77030, USA. Electronic address:

Derosa et al. demonstrated that intestinal Akkermansia muciniphila predicts vigorous response to immunotherapy in non-small-cell lung cancer. Baseline level of this microbe has better value than PD-L1 expression and represents a unique approach for stratifying patients that can benefit from immunotherapy. Read More

View Article and Full-Text PDF

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.

JCO Precis Oncol 2022 May;6:e2100522

Department of Medicine, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.

Purpose: The CNS is a recurrent site of progression in anaplastic lymphoma kinase (ALK)-rearranged (ALK+) lung cancer. Lorlatinib is a third-generation ALK inhibitor developed to penetrate the CNS and overcome resistance mutations. We conducted a phase II study to evaluate the intracranial activity of lorlatinib in patients with CNS-only progression on second-generation ALK inhibitors. Read More

View Article and Full-Text PDF

[Targeted therapies and non-small cell carcinomas : novelties].

Rev Med Suisse 2022 May;18(782):970-975

Service d'oncologie médicale, Département d'oncologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.

In recent years, new therapeutic strategies for non-small cell lung cancer (NSCLC) have been developed, stemming from a better understanding of oncogenic signaling pathways. The analysis of the alterations of genes involved in NSCLC oncogenesis is now an integral part of the diagnostic approach and opens the way to so-called "targeted" therapies. In this article, we will share the latest therapeutic advances by focusing on alterations of HER2, MET, EGFR and KRAS genes, for which new dedicated treatments have become available. Read More

View Article and Full-Text PDF

Colony‑stimulating factor CSF2 mediates the phenotypic plasticity of small‑cell lung cancer by regulating the p‑STAT3/MYC pathway.

Oncol Rep 2022 Jul 18;48(1). Epub 2022 May 18.

Translational Cancer Research Lab, Jilin Cancer Hospital, Changchun, Jilin 130000, P.R. China.

Relapse and drug resistance are the main causes of mortality in patients with small‑cell lung cancer (SCLC). Intratumoral heterogeneity (ITH) is a key biological mechanism that leads to relapse and drug resistance. Phenotypic plasticity is an important factor that leads to ITH in SCLC, although its mechanisms and key regulatory factors remain to be elucidated. Read More

View Article and Full-Text PDF

Polymyositis as a paraneoplastic syndrome of a patient with primary pulmonary lymphoepithelioma-like carcinoma: a case report and literature review.

J Cardiothorac Surg 2022 May 17;17(1):120. Epub 2022 May 17.

Department of Cardiothoracic Surgery, The First People's Hospital of Neijiang, Shizhong District, No. 1866, West Section of Hanan Avenue, Neijiang, 641000, Sichuan, China.

Background: Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of non-small cell lung cancer, which mostly occurred in non-smoking Asian populations. The prognosis of this tumor is better than other lung cancers. Polymyositis, a kind of idiopathic inflammatory myopathies, may negatively affect the prognosis of patients with lung cancer as a paraneoplastic syndrome (PNPS). Read More

View Article and Full-Text PDF

SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer.

BMC Med Genomics 2022 May 17;15(1):114. Epub 2022 May 17.

Department of Organic Chemistry and Medicinal Chemistry, Pharmaceutical College, Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.

Background: The roles and clinical values of synaptojanin 2 (SYNJ2) in lung squamous cell carcinoma (LUSC) remain unclear.

Methods: A total of 2824 samples from multi-center were collected to identify the expression of SYNJ2 in LUSC by using Wilcoxon rank-sum test, t-test, and standardized mean difference (SMD), and 194 in-house samples were also included to validate SYNJ2 expression in LUSC. The clinical roles of SYNJ2 were investigated via receiver operating characteristic (ROC) curves, univariate Cox regression analysis, and Kaplan-Meier plots. Read More

View Article and Full-Text PDF

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.

Lab Invest 2022 May 17. Epub 2022 May 17.

Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.

Immune checkpoint blockade with programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has resulted in significant progress in the treatment of various cancer types. However, not all patients respond to PD-1/PD-L1 blockade, underscoring the importance of identifying new potential targets for immunotherapy. One promising target is the immune system modulator Siglec-15. Read More

View Article and Full-Text PDF

The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non-small cell lung cancer.

Thorac Cancer 2022 May 17. Epub 2022 May 17.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Background: Research has shown that some microbiomes are linked to cancer. Hence, we hypothesize that alterations in the respiratory microbiome might be associated with lung cancer.

Methods: Through droplet digital polymerase chain reaction analysis, we investigated the abundance of Acidovorax in surgically resected primary tumors and corresponding nontumor lung tissues obtained from 50 Japanese patients with non-small cell lung cancer. Read More

View Article and Full-Text PDF

Cyclophilin A represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein.

Authors:
Yang Li Lan Yang

Cell Cycle 2022 May 17. Epub 2022 May 17.

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, Shaanxi 710061, P.R. China.

Cyclophilin A (cypA) is overexpressed in many types of carcinomas, including non-small-cell lung cancer (NSCLC). However, the effect of anoxia, a critical feature of the carcinoma cell microenvironment, on cypA expression in NSCLC is unknown. Here, formaldehyde-fixed and paraffin-embedded samples were collected from 60 subjects with NSCLC. Read More

View Article and Full-Text PDF

Radiation therapy and immunotherapy in locally advanced NSCLC.

Authors:
Percy Lee

Clin Adv Hematol Oncol 2022 May;20(5):288-290

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article and Full-Text PDF

[A Case of Non-Small Cell Lung Cancer Successfully Treated with Anti-PD-L1 Therapy after Exacerbation Caused by Anti-PD-1 Therapy].

Gan To Kagaku Ryoho 2022 May;49(5):569-571

Dept. of Medical Oncology, Ageo Central General Hospital.

A 52-year-old male was diagnosed with cT4N3M1b, cStage Ⅳ adenocarcinoma of the lung, and underwent 6 courses of pemetrexed(PEM), carboplatin(CBDCA), and bevacizumab(Bev)therapy, followed by 4 courses of PEM/Bev maintenance therapy. Due to the deterioration of his condition, 4 courses of pembrolizumab(Pembro)therapy were administered as second- line therapy, but the treatment was discontinued due to disease progression. Third-line therapy with docetaxel(DTX)/ ramucirumab(Rmab)was administered, resulting in a partial response, but discontinued due to adverse events. Read More

View Article and Full-Text PDF

ZFPM2-AS1: An Oncogenic Long Non-coding RNA in Multiple Cancer Types.

Authors:
Fangshun Tan

Mini Rev Med Chem 2022 May 16. Epub 2022 May 16.

Medical College, China Three Gorges University, Yichang 443002, China.

Long non-coding RNA (lncRNA) is a novel kind of RNA transcript with lengths greater than 200 nucleotides. Functionally, lncRNAs lack the potential to encode peptides or proteins. Previous studies unveiled that lncRNA participated in numerous physiological and pathological processes, including cancer, aging, and immune responses. Read More

View Article and Full-Text PDF